Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth John & Brother LtdfiledCriticalWyeth John & Brother Ltd
Priority to TW83100034ApriorityCriticalpatent/TW257759B/en
Application grantedgrantedCritical
Publication of TW257759BpublicationCriticalpatent/TW257759B/en
Piperazine derivatives of formula (see claim 1) and their pharmaceutically acceptable salts are 5-HT1A binding agents and may be used, for example, as anxiolytics. In the formula R1 is unsubstituted phenyl, phenyl substituted by lower alkoxy or lower alkyl, isoquinolinyl, or pyrimidinyl. R2 is unsubstituted phenyl, phenyl substituted by lower alkyl, lower alkoxy, NO2, phenyl, or unsubstituted pyridyl, pyridyl substituted by low alkyl, and n is 1 or 2 and m is 1 to 3 and the total of n + m is 2-4.
7-Amino-1-cyclopropyl-6,8-dihalo-1,4-dihydro-4-oxo-3-quinoline-carboxylic acids, process for their preparation and bactericidal agents containing them.